AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31358597 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis
Number of subjects: 40004
Study 31359190 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm to brainstem ratio (ABR) in medial group
Number of subjects: 28
Study 31359190 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm to brainstem ratio (ABR) in lateral group
Number of subjects: 28
Study 31359190 — intervention group
Group type: EXPERIMENTAL
Intervention: Giant intracranial aneurysm volumes
Number of subjects: 28
Study 31359190 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainstem compression ratio (BCR) in medial group
Number of subjects: 28
Study 31359190 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainstem compression ratio (BCR) in lateral group
Number of subjects: 28
Study 31359304 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ embolization combined with surgical resection
Number of subjects: 9
Study 31359361 — intervention group
Group type: EXPERIMENTAL
Intervention: quizartinib 20 mg/day
Number of subjects: 16
Study 31359361 — intervention group
Group type: EXPERIMENTAL
Intervention: quizartinib 30 mg/day
Number of subjects: 16
Study 31359361 — intervention group
Group type: EXPERIMENTAL
Intervention: quizartinib 60 mg/day
Number of subjects: 16
Study 31359361 — intervention group
Group type: EXPERIMENTAL
Intervention: quizartinib
Number of subjects: 16
Study 31359403 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) based on resting metabolic rate (RMR) and 3-month structured exercise training (SSET)
Number of subjects: 23
Study 31359403 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention with SSET and CR
Number of subjects: 23
Study 31359808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0
Study 31359863 — intervention group
Group type: EXPERIMENTAL
Intervention: myBETAapp usage
Number of subjects: 94
Study 31359863 — intervention group
Group type: EXPERIMENTAL
Intervention: wellness tracker usage
Number of subjects: 94
Study 31359874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained virological response (SVR) using direct-acting antiviral therapies
Number of subjects: 162
Study 31360532 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive echocardiography protocol including transthoracic and transesophageal echocardiography.
Number of subjects: 0
Study 31360532 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of conventional and unconventional vascular risk factors.
Number of subjects: 0
Study 31360532 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel pathophysiological brain-heart pathways.
Number of subjects: 0
Study 31360988 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of phosphatidylcholine intake
Number of subjects: 2497
Study 31360988 — intervention group
Group type: EXPERIMENTAL
Intervention: Total choline intake
Number of subjects: 2497
Study 31360988 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of total choline and phosphatidylcholine
Number of subjects: 2497
Study 31361205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac MRI with texture analysis of T1 and T2 maps
Number of subjects: 71
Study 31361205 — intervention group
Group type: COMPARATOR
Intervention: Endomyocardial biopsy (EMB)
Number of subjects: 71
Study 31361303 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 23
Study 31361303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant therapy
Number of subjects: 23
Study 31361303 — intervention group
Group type: COMPARATOR
Intervention: Active acromegaly
Number of subjects: 23
Study 31362540 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-mm Meridian valve
Number of subjects: 25
Study 31362654 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cell transplantation with LentiGlobin (HGB-207 trial)
Number of subjects: 0
Study 31362654 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (herbal therapeutic approach)
Number of subjects: 0
Study 31362654 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (HSCT)
Number of subjects: 0
Study 31362654 — intervention group
Group type: EXPERIMENTAL
Intervention: ActRIIB/IgG1 Fc recombinant protein
Number of subjects: 0
Study 31362654 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene correction strategies (e.g., suppression of BCL11A, HPFH, zinc-finger nucleases)
Number of subjects: 0
Study 31363416 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus audio-recorded discharge discussion
Number of subjects: 50
Study 31363416 — intervention group
Group type: COMPARATOR
Intervention: Usual care (verbal discussion and written summary)
Number of subjects: 50
Study 31364010 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13), two doses 8 weeks apart
Number of subjects: 91
Study 31364010 — intervention group
Group type: COMPARATOR
Intervention: 23-valent polysaccharide vaccine (PPV23), one dose
Number of subjects: 91
Study 31364233 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible BI/GLP-1RA combination
Number of subjects: 609
Study 31364233 — intervention group
Group type: COMPARATOR
Intervention: Fixed BI/GLP-1RA combination
Number of subjects: 609
Study 31364451 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 800
Study 31364451 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple potential embolic sources (PES)
Number of subjects: 800
Study 31364451 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention reported
Number of subjects: 800
Study 31364457 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM), specifically Salvia miltiorrhiza, administered intravenously to 74.7% of patients.
Number of subjects: 10004
Study 31364457 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) use in hospitals (99.4% of hospitals used TCM).
Number of subjects: 10004
Study 31364457 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with coronary artery disease.
Number of subjects: 10004
Study 31364457 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stroke.
Number of subjects: 10004
Study 31364601 — intervention group
Group type: EXPERIMENTAL
Intervention: YouTHrive (YT) intervention - access to the YT site for 5 months
Number of subjects: 300
Study 31364601 — intervention group
Group type: COMPARATOR
Intervention: Control group - weekly email newsletter on HIV topics excluding ART adherence for 5 months
Number of subjects: 300
Study 31364602 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined intervention (beta-i) for increasing small businesses' involvement with YPAOs.
Number of subjects: 10
Study 31364602 — intervention group
Group type: COMPARATOR
Intervention: Standard practice intervention provided to the control group of neighborhoods.
Number of subjects: 10
Study 31364979 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 1020
Study 31364979 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 1020
Study 31364979 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 25 mg
Number of subjects: 1020
Study 31365116 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 256
Study 31365335 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 244
Study 31366074 — intervention group
Group type: EXPERIMENTAL
Intervention: Catestatin (CST) levels in ADHF patients with MI history
Number of subjects: 90
Study 31366330 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia (OFA) with lidocaine, dexamethasone, and ketamine
Number of subjects: 110
Study 31366330 — intervention group
Group type: COMPARATOR
Intervention: Opioid anaesthesia (OA) with sufentanil
Number of subjects: 110
Study 31366330 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-free anaesthesia (OFA)
Number of subjects: 110
Study 31366330 — intervention group
Group type: COMPARATOR
Intervention: Opioid anaesthesia (OA)
Number of subjects: 110
Study 31366659 — intervention group
Group type: EXPERIMENTAL
Intervention: PreLiFe programme
Number of subjects: 460
Study 31366659 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 460
Study 31367455 — intervention group
Group type: EXPERIMENTAL
Intervention: Living kidney donation
Number of subjects: 1042
Study 31367462 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic yoga (DY) intervention
Number of subjects: 75
Study 31367462 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver yoga (CY) intervention
Number of subjects: 75
Study 31367462 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC) group
Number of subjects: 75
Study 31367462 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (DY, CY, WLC)
Number of subjects: 75
Study 31367468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks until no evidence of fluid, then 2 mg every 8 weeks
Number of subjects: 20
Study 31367468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI)
Number of subjects: 20
Study 31367511 — intervention group
Group type: EXPERIMENTAL
Intervention: Before-school physical activity program (BOKS)
Number of subjects: 0
Study 31367511 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31367538 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² and sirolimus (oral daily after loading dose)
Number of subjects: 42
Study 31367691 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with 1 Hass avocado daily
Number of subjects: 51
Study 31367691 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet without Hass avocado
Number of subjects: 51
Study 31367759 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy expenditure predictions
Number of subjects: 0
Study 31368034 — intervention group
Group type: EXPERIMENTAL
Intervention: Taselisib (2-6 mg tablet or 3-6 mg capsule) plus docetaxel
Number of subjects: 80
Study 31368034 — intervention group
Group type: EXPERIMENTAL
Intervention: Taselisib (2-6 mg tablet or 3-6 mg capsule) plus paclitaxel
Number of subjects: 80
Study 31368401 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying therapies (DMTs)
Number of subjects: 377
Study 31368401 — intervention group
Group type: EXPERIMENTAL
Intervention: External locus of control (influential others such as physicians)
Number of subjects: 377
Study 31368401 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-active disease status
Number of subjects: 377
Study 31368441 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming (EXG)
Number of subjects: 22
Study 31368441 — intervention group
Group type: COMPARATOR
Intervention: Treadmill exercise (TE)
Number of subjects: 22
Study 31368720 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment for eating disorders with a focus on trauma work, fostering patient agency, and relational dynamics in patient-therapist dyad.
Number of subjects: 11
Study 31368718 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 100
Study 31368718 — intervention group
Group type: EXPERIMENTAL
Intervention: Former/current smoking status
Number of subjects: 100
Study 31368718 — intervention group
Group type: COMPARATOR
Intervention: Former vs. current smokers
Number of subjects: 100
Study 31368718 — intervention group
Group type: COMPARATOR
Intervention: Global sleep quality, sleep latency, and sleep efficiency
Number of subjects: 100
Study 31368742 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime history of TBI
Number of subjects: 1060
Study 31368742 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent deployment-related mild TBIs
Number of subjects: 1060
Study 31368837 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31369089 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84) 25 or 50 µg/d initially, with 25-µg adjustments permitted to a 100 µg/d maximum
Number of subjects: 49
Study 31369089 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Number of subjects: 49
Study 31369102 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-depleted diet
Number of subjects: 12
Study 31369102 — intervention group
Group type: COMPARATOR
Intervention: Tetracosactide test in GS patients
Number of subjects: 12
Study 31369217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dancing people versus dynamic geometrical images
Number of subjects: 69
Study 31369217 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological motion (dynamic light point walking human or cat) versus nonbiological motion (scrambled controls)
Number of subjects: 69
Study 31369217 — intervention group
Group type: EXPERIMENTAL
Intervention: Child playing with toy versus toy alone
Number of subjects: 69
Study 31369400 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended weight gain (n=8, 15%) during the second and third trimesters
Number of subjects: 54
Study 31369400 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess weight gain (67%)
Number of subjects: 54
Study 31369400 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended energy balance
Number of subjects: 54
Study 31369400 — intervention group
Group type: EXPERIMENTAL
Intervention: Excess energy balance
Number of subjects: 54
Study 31369400 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate energy balance
Number of subjects: 54
Study 31369400 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake requirements for recommended weight gain during the second and third trimesters
Number of subjects: 54
Study 31369558 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Kato-Katz (reference method)
Number of subjects: 0
Study 31369558 — intervention group
Group type: EXPERIMENTAL
Intervention: qPCR
Number of subjects: 0
Study 31369558 — intervention group
Group type: COMPARATOR
Intervention: Mini-FLOTAC
Number of subjects: 0
Study 31369558 — intervention group
Group type: COMPARATOR
Intervention: FECPAKG2
Number of subjects: 0
Study 31369558 — intervention group
Group type: COMPARATOR
Intervention: Single Kato-Katz
Number of subjects: 0
Study 31369562 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (ALB)
Number of subjects: 0
Study 31369562 — intervention group
Group type: COMPARATOR
Intervention: Kato-Katz (single and duplicate)
Number of subjects: 0
Study 31369562 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-FLOTAC
Number of subjects: 0
Study 31369562 — intervention group
Group type: EXPERIMENTAL
Intervention: FECPAKG2
Number of subjects: 0
Study 31369562 — intervention group
Group type: EXPERIMENTAL
Intervention: qPCR
Number of subjects: 0
Study 31369720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower peak and accelerated decline in FEV
Number of subjects: 3171
Study 31369873 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional ATP sequences (>3 in VT zone or >1 in FVT zone)
Number of subjects: 4112
Study 31369873 — intervention group
Group type: COMPARATOR
Intervention: Nominal group (≤3 ATP sequences in VT zone or ≤1 ATP sequence in FVT zone)
Number of subjects: 4112
Study 31370698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential afatinib followed by osimertinib
Number of subjects: 0
Study 31370866 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A deficiency in septic children
Number of subjects: 160
Study 31370869 — intervention group
Group type: EXPERIMENTAL
Intervention: Hebrew version of the Western Ontario Shoulder Instability index (WOSI)
Number of subjects: 25
Study 31370907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum smoking
Number of subjects: 77
Study 31370907 — intervention group
Group type: COMPARATOR
Intervention: Overnight smoking abstinence
Number of subjects: 77
Study 31370954 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS inhibitors
Number of subjects: 2785
Study 31370978 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of fentanyl in heroin
Number of subjects: 239
Study 31370978 — intervention group
Group type: EXPERIMENTAL
Intervention: Past month injection drug use
Number of subjects: 239
Study 31371173 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 hours of procedural simulation training for difficult airway management
Number of subjects: 60
Study 31371173 — intervention group
Group type: EXPERIMENTAL
Intervention: Malleable intubation stylet
Number of subjects: 60
Study 31371173 — intervention group
Group type: EXPERIMENTAL
Intervention: Eschmann introducer
Number of subjects: 60
Study 31371173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 31371173 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary endpoint (frequency of use of devices)
Number of subjects: 60
Study 31371191 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban treatment in patients with WRF
Number of subjects: 7509
Study 31371191 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban treatment in patients with SRF
Number of subjects: 7509
Study 31371262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort A (no lopinavir resistance) - second-line ART
Number of subjects: 545
Study 31371262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort B1 (best available NRTIs plus ritonavir-boosted darunavir plus raltegravir)
Number of subjects: 545
Study 31371262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort B2 (ritonavir-boosted darunavir plus raltegravir plus etravirine)
Number of subjects: 545
Study 31371262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort B3 (ritonavir-boosted darunavir, raltegravir, and either tenofovir plus emtricitabine or tenofovir plus lamivudine)
Number of subjects: 545
Study 31371262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort C (ritonavir-boosted darunavir plus raltegravir plus tenofovir-emtricitabine or tenofovir plus lamivudine)
Number of subjects: 545
Study 31371262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort D (best available NRTIs plus ritonavir-boosted darunavir plus raltegravir)
Number of subjects: 545
Study 31371262 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all cohorts)
Number of subjects: 545
Study 31371339 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 194
Study 31371339 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 194
Study 31371339 — intervention group
Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 194
Study 31371339 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 194
Study 31371345 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB054828 (pan-FGFR inhibitor)
Number of subjects: 1
Study 31371350 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized OncoGenomics (POG) program
Number of subjects: 16
Study 31371411 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET imaging
Number of subjects: 0
Study 31371411 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical assessment
Number of subjects: 0
Study 31371414 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX) treatment, 5 g/m², during consolidation therapy.
Number of subjects: 1212
Study 31371644 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose statin treatment
Number of subjects: 77
Study 31371644 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial LDL-C levels
Number of subjects: 77
Study 31371644 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up LDL-C levels
Number of subjects: 77
Study 31372055 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib with gemcitabine/cisplatin or carboplatin
Number of subjects: 39
Study 31372236 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 44
Study 31372236 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP-Sym 18 Questionnaire
Number of subjects: 44
Study 31372236 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-Life Function and Disability Instrument (LLFDI)
Number of subjects: 44
Study 31372236 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility measures
Number of subjects: 44
Study 31372961 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefilled Syringe (PFS)
Number of subjects: 54
Study 31372961 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoinjector (AI)
Number of subjects: 54
Study 31372961 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PFS and AI
Number of subjects: 54
Study 31373273 — intervention group
Group type: EXPERIMENTAL
Intervention: A-CHESS mobile health application with HCV intervention content including educational information, tailored messages, and a public discussion forum.
Number of subjects: 416
Study 31373273 — intervention group
Group type: COMPARATOR
Intervention: Control group (details of the control intervention are not specified in the abstract).
Number of subjects: 416
Study 31373712 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised mesalazine therapy
Number of subjects: 268
Study 31374300 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg dupilumab weekly for up to 76 weeks
Number of subjects: 1491
Study 31374487 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide ≤8 mg/kg/day for Cohort 1 (aged 5-11 years); ≤12 mg/kg/day (≤600 mg/day) for age-based cohorts 2-5
Number of subjects: 47
Study 31374487 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide treatment
Number of subjects: 47
Study 31374571 — intervention group
Group type: EXPERIMENTAL
Intervention: CT individuals
Number of subjects: 60
Study 31375031 — intervention group
Group type: EXPERIMENTAL
Intervention: OneTouch Verio Reflect
Number of subjects: 0
Study 31375031 — intervention group
Group type: EXPERIMENTAL
Intervention: OneTouch Ultra Plus Reflect
Number of subjects: 0
Study 31375393 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine treatment
Number of subjects: 116
Study 31375469 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA PET tracer
Number of subjects: 50
Study 31375510 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cholesterol efflux capacity (CEC)
Number of subjects: 405
Study 31375510 — intervention group
Group type: EXPERIMENTAL
Intervention: NODAT incidence
Number of subjects: 405
Study 31375516 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of uniparental disomy (UPD)
Number of subjects: 109
Study 31375516 — intervention group
Group type: EXPERIMENTAL
Intervention: UPD on chromosome arm 13q
Number of subjects: 109
Study 31375516 — intervention group
Group type: EXPERIMENTAL
Intervention: UPD on chromosome arm 6p
Number of subjects: 109